Home » Topics » BioWorld Science

BioWorld Science
RSS

Predicting phase separation

Feb. 10, 2021

European Commission approves Inrebic for newly diagnosed and previously treated myelofibrosis

Feb. 9, 2021

KalVista releases phase II data on KVD-900 as oral on-demand treatment for HAE

Feb. 9, 2021

Positive interim phase I data presented for COVID-19 vaccine candidate UB-612

Feb. 9, 2021

Jasper Therapeutics presents phase I data for anti-CD117 JSP-191 MAb

Feb. 9, 2021

AVROBIO reports new advances with upgraded gene therapy platform

Feb. 9, 2021

ImmunoMet Therapeutics set to begin phase I U.S. study of IM-156 in IPF

Feb. 9, 2021

FDA clears Catapult's IND for phase I trial of CAP-100 in CLL

Feb. 9, 2021

Innovent begins pivotal study of IBI-310 with sintilimab for first-line advanced HCC

Feb. 9, 2021

Ad5-nCoV vaccine meets prespecified primary safety and efficacy criteria for phase III study

Feb. 9, 2021

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...